James R. Gnarra

James R. Gnarra

Auto-generated profile, based on publicly available information

James R. Gnarra

Cell Biology and Metabolism Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 1993 in Science
Verified
Journal Article
Closed access
PDF file
FLFarida Latif
Farida Latif
KTKalman Tory
Kalman Tory
JGJames Gnarra
James Gnarra
MYMasahiro Yao
Masahiro Yao
FDFuh-Mei Duh
Fuh-Mei Duh
AEAl. Et
Al. Et
A gene discovered by positional cloning has been identified as the von Hippel-Lindau (VHL) disease tumor suppressor gene. A restriction fragment encompassing the gene showed rearrangements in 28 of 221 VHL kindreds. Eighteen of these rearrangements were due to deletions in the candidate gene, including three large nonoverlapping deletions. Intragenic mutations were detected in cell lines derived from VHL patients and from sporadic renal cell carcinomas. The VHL gene is evolutionarily conserved and encodes two widely expressed transcripts of approximately 6 and 6.5 kilobases. The partial sequence of the inferred gene product shows no homology to other proteins, except for an acidic repeat domain found in the procyclic surface membrane glycoprotein of Trypanosoma brucei .

1 May 1994 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JGJ.R. Gnarra
J.R. Gnarra
KTK. Tory
K. Tory
YWY. Weng
Y. Weng
LSL. Schmidt
L. Schmidt
MWM.H. Wei
M.H. Wei
WLW.M. Linehan
W.M. Linehan

11 October 1994 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JHJ G Herman
J G Herman
FLF Latif
F Latif
YWY Weng
Y Weng
MLM I Lerman
M I Lerman
BZB Zbar
B Zbar
WLW M Linehan
W M Linehan
Mutational inactivation and allelic loss of the von Hippel-Lindau (VHL) gene appear to be causal events for the majority of spontaneous clear-cell renal carcinomas. We now show that hypermethylation of a normally unmethylated CpG island in the 5' region provides another potentially important mechanism for inactivation of the VHL gene in a significant portion of these cancers. This hypermethylation was found in 5 of 26 (19%) tumors examined. Four of these had lost one copy of VHL while one retained two heavily methylated alleles. Four of the tumors with VHL hypermethylation had no detectable mutations, whereas one had a missense mutation in addition to hypermethylation of the single retained allele. As would be predicted for the consequence of methylation in this 5' CpG island, none of the 5 tumors expressed the VHL gene. In contrast, normal kidney and all tumors examined with inactivating VHL gene mutations but no CpG island methylation had expression. In a renal cell culture line, treatment with 5-aza-2'-deoxycytidine resulted in reexpression of the VHL gene. These findings suggest that aberrant methylation of CpG islands may participate in the tumor-suppressor gene inactivations which initiate or cause progression of common human cancers.

1 January 1995 in Human Mutation
Verified
Journal Article
Closed access
PDF file
FCFan Chen
Fan Chen
TKTakeshi Kishida
Takeshi Kishida
MYMasahiro Yao
Masahiro Yao
THThomas Hustad
Thomas Hustad
DGDamjan Glavac
Damjan Glavac
BZBerton Zbar
Berton Zbar
Von Hippel‐Lindau disease (VHL) is an inherited neoplastic disease characterized by a predisposition to develop retinal angiomas, central nervous system hemangioblastomas, renal cell carcinomas, pancreatie cysts, and pheochromocytomas. The VHL gene was recently isolated by positional cloning. The cDNA encodes 852 nucleotides in 3 exons. The VHL gene is unrelated to any known gene families. We identified germline mutations in 85/114 (75%) of VHL families. Clinical heterogeneity is a well‐known feature of VHL. VHL families were classified into 2 types based on the presence or absence of pheochromocytoma. The types of mutations responsible for VHL without pheochromocytoma (VHL type 1) differed from those responsible for VHL with pheochromocytoma (VHL type 2). Fifty‐six % of the mutations responsible for VHL type l were microdeletions/insertions, nonsense mutations, or deletions; 96% of the mutations responsible for VHL type 2 were missense mutations. Specific mutations in codon 238 accounted for 43% of the mutations responsible for VHL type 2. The mutations identified in these families will be useful in presymptomatic diagnosis. The identification of mutations associated with phenotypes contributes to the understanding of fundamental genetic mechanisms of VHL disease.

1 October 1996 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JGJ R Gnarra
J R Gnarra
SZS Zhou
S Zhou
MMM J Merrill
M J Merrill
JWJ R Wagner
J R Wagner
AKA Krumm
A Krumm
WLW M Linehan
W M Linehan
The VHL tumor suppressor gene is inactivated in patients with von Hippel-Lindau disease and in most sporadic clear cell renal carcinomas. Although VHL protein function remains unclear, VHL does interact with the elongin BC subunits in vivo and regulates RNA polymerase II elongation activity in vitro by inhibiting formation of the elongin ABC complex. Expression of wild-type VHL in renal carcinoma cells with inactivated endogenous VHL resulted in unaltered in vitro cell growth and decreased vascular endothelial growth factor (VEGF) mRNA expression and responsiveness to serum deprivation. VEGF is highly expressed in many tumors, including VHL-associated and sporadic renal carcinomas, and it stimulates neoangiogenesis in growing solid tumors. Despite 5-fold differences in VEGF mRNA levels, VHL overexpression did not affect VEGF transcription initiation or elongation as would have been suggested by VHL-elongin association. These results suggest that VHL regulates VEGF expression at a post-transcriptional level and that VHL inactivation in target cells causes a loss of VEGF suppression, leading to formation of a vascular stroma.

19 August 1997 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JGJames R. Gnarra
James R. Gnarra
JWJerrold M. Ward
Jerrold M. Ward
FPForbes D. Porter
Forbes D. Porter
JWJoseph R. Wagner
Joseph R. Wagner
DDDeborah E. Devor
Deborah E. Devor
WLW. Marston Linehan
W. Marston Linehan
Inheritance of an inactivated form of the VHL tumor suppressor gene predisposes patients to develop von Hippel–Lindau disease, and somatic VHL inactivation is an early genetic event leading to the development of sporadic renal cell carcinoma. The VHL gene was disrupted by targeted homologous recombination in murine embryonic stem cells, and a mouse line containing an inactivated VHL allele was generated. While heterozygous VHL (+/−) mice appeared phenotypically normal, VHL −/− mice died in utero at 10.5 to 12.5 days of gestation (E10.5 to E12.5). Homozygous VHL −/− embryos appeared to develop normally until E9.5 to E10.5, when placental dysgenesis developed. Embryonic vasculogenesis of the placenta failed to occur in VHL −/− mice, and hemorrhagic lesions developed in the placenta. Subsequent hemorrhage in VHL −/− embryos caused necrosis and death. These results indicate that VHL expression is critical for normal extraembryonic vascular development.